The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study
Table 2
Characteristics between SMT and ALSS before PSM.
Variates
SMT
ALSS
value
321
50
Age (year)
0.011
HBV-DNA (log copies/mL)
0.986
Male sex
240 (74.80)
42 (84.00)
0.213
Degree of HE
0.322
Without HE
179 (55.80)
23 (46.00)
I
49 (15.30)
6 (12.00)
II
27 (8.40)
7 (14.00)
III
20 (6.20)
6 (12.00)
IV
46 (14.30)
8 (16.00)
Ascitic (%)
0.003
Grade 1
58 (17.00)
12 (24.00)
Grade 2
87 (27.10)
23 (46.00)
Grade 3
115 (35.80)
7 (14.00)
Missing data
61 (19.00)
8 (16.00)
MAP (mmHg)
0.682
HR
0.428
INR
1.84 (1.46-2.33)
2.08 (1.74-2.63)
0.137
WBC (109/L)
7.40 (4.98-11.40)
6.55 (5.05-9.58)
0.072
Neutrophil (%)
0.047
Albumin (g/L)
0.686
Globulin (g/L)
0.677
ALT (U/L)
44.50 (22.00-104.20)
114.00 (54.75-253.50)
0.060
AST (U/L)
70.00 (39.00-154.20)
144.50 (92.50-282.00)
0.202
Hemoglobin (g/L)
<0.001
Cystatin C (mg/L)
2.14 (1.53-3.41)
1.24 (0.92-1.70)
0.002
Urea (mmol/L)
14.40 (8.50-23.75)
7.95 (4.23-14.50)
0.006
Creatinine (mg/dL)
1.75 (1.01-2.75)
0.93 (0.71-1.61)
0.001
Serum bilirubin (mg/dL)
12.61 (2.51-24.09)
20.07 (10.64-28.13)
0.011
GGT (U/L)
59.00 (33.00-123.00)
61.50 (45.75-99.50)
0.393
Potassium (mmol/L)
0.627
Sodium (mmol/L)
0.208
MELDs
0.979
iMELD
0.179
CTP
0.011
CLIF-ACLFs
0.408
CLIF-SOFAs
0.499
COSSH-ACLFs
0.988
Liver failure
163 (50.80)
35 (70.00)
0.017
Coagulation failure
68 (21.20)
16 (32.00)
0.129
Cerebral failure
66 (20.60)
0 (0.00)
0.315
28-day mortality
190 (59.20)
24 (48.00)
0.182
ALT: alanine aminotransferase; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; COSSH-ACLF: Chinese Group on the Study of Severe Hepatitis B-Acute-on-Chronic Liver Failure; HBV: hepatitis B virus; INR: International normalized ratio; MAP: Mean arterial pressure; MELD: Model for End-Stage Liver Disease.
